ACN Stock Analysis: Accenture | NYSE
Information Technology Services | NYSE, USA | Market Cap: 127.504m USD | 12M Return: -9.4% | IE00B4BNMY34 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.21B
EPS Trend: 99.0%
Qual. Beats: 4
Rev. Trend: 98.2%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Accenture plc (NYSE: ACN) is a global professional services firm headquartered in Dublin, Ireland, founded in 1951 and listed on the NYSE since 2001. The company operates across the Americas, Europe, the Middle East, Africa, and Asia Pacific, serving industries including communications and technology, financial services, banking and capital markets, insurance, health and public service, consumer goods, retail, industrial, life sciences, and energy and utilities.
Its service portfolio spans strategy and consulting, technology and operations, systems integration, application management, data and AI, cloud, automation, and security, as well as managed business processes for functions like finance, procurement, supply chain, and human resources. The IT consulting industry in which Accenture competes is characterized by long-term, multi-billion-dollar enterprise contracts and a shift toward cloud-based and AI-driven delivery models.
Accenture has active partnerships with major technology providers, including Amazon Web Services (AWS), OpenAI, Microsoft, Avanade, SAP Japan, Netomi, and ServiceNow, many focused on deploying generative and agentic AI solutions. These alliances support joint go-to-market initiatives in areas such as public sector digital services, enterprise AI adoption, customer experience automation, and integrated risk management.
- Generative AI bookings accelerate, lifting consulting revenue
- Federal government IT budget cuts pressure largest segment
- European weakness and FX headwinds weigh on reported growth
| Net Income: 8.40b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -0.84 > 1.0 |
| NWC/Revenue: 12.84% < 20% (prev 12.27%; Δ 0.57% < -1%) |
| CFO/TA 0.17 > 3% & CFO 12.4b > Net Income 8.40b |
| Net Debt (3.81b) to EBITDA (13.3b): 0.29 < 3 |
| Current Ratio: 1.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (605.3m) vs 12m ago -3.83% < -2% |
| Gross Margin: 32.01% > 18% (prev 31.91%; Δ 0.10% > 0.5%) |
| Asset Turnover: 106.7% > 50% (prev 106.5%; Δ 0.20% > 0%) |
| Interest Coverage Ratio: 38.48 > 6 (EBIT TTM 11.7b / Interest Expense TTM 303.4m) |
| A: 0.13 (Total Current Assets 31.8b - Total Current Liabilities 22.3b) / Total Assets 73.6b |
| B: 0.33 (Retained Earnings 24.0b / Total Assets 73.6b) |
| C: 0.17 (EBIT TTM 11.7b / Avg Total Assets 69.5b) |
| D: 0.78 (Book Value of Equity 31.6b / Total Liabilities 40.3b) |
| Altman-Z'' = 3.86 = AA |
| DSRI: 1.02 (Receivables 16.3b/15.0b, Revenue 74.2b/69.7b) |
| GMI: 1.00 (GM 31.91% / 32.01%) |
| AQI: 1.02 (AQ_t 0.50 / AQ_t-1 0.49) |
| SGI: 1.06 (Revenue 74.2b / 69.7b) |
| TATA: -0.05 (NI 8.40b - CFO 12.4b) / TA 73.6b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of October 13, 2026, the stock is trading at USD 214.87 with a total of 6,387,075 shares traded. Over the past week, the price has changed by +10.16%, over one month by +10.19%, over three months by +55.12% and over the past year by -9.44%.
Current recommended Stop Loss: 203.20 (which is 5.4% or 1.3 ATR below the current price).
Accenture has received a consensus analysts rating of 3.78. Therefore, it is recommended to hold ACN.
- StrongBuy: 9
- Buy: 3
- Hold: 15
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 223.7 | 4.1% |
P/E Trailing = 15.3658
P/E Forward = 12.4069
P/S = 1.7188
P/B = 3.5215
P/EG = 1.3333
Revenue TTM = 74.2b USD
EBIT TTM = 11.7b USD
EBITDA TTM = 13.3b USD
Long Term Debt = 5.03b USD (from longTermDebt, two quarters ago)
Short Term Debt = 881.4m USD (from shortTermDebt, last quarter)
Debt = 16.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 3.25b
Net Debt = 3.81b USD (calculated: Debt 16.6b - CCE 12.8b)
Enterprise Value = 131b USD (128b + Debt 16.6b - CCE 12.8b)
Interest Coverage Ratio = 38.48 (Ebit TTM 11.7b / Interest Expense TTM 303.4m)
EV/FCF = 11.30x (Enterprise Value 131b / FCF TTM 11.6b)
FCF Yield = 8.85% (FCF TTM 11.6b / Enterprise Value 131b)
FCF Margin = 15.66% (FCF TTM 11.6b / Revenue TTM 74.2b)
Net Margin = 11.32% (Net Income TTM 8.40b / Revenue TTM 74.2b)
Gross Margin = 32.01% ((Revenue TTM 74.2b - Cost of Revenue TTM 50.4b) / Revenue TTM)
Gross Margin QoQ = 32.04% (prev 32.77%)
Tobins Q-Ratio = 1.78 (Enterprise Value 131b / Total Assets 73.6b)
Interest Expense / Debt = 1.82% (Interest Expense 303.4m / Debt 16.6b)
Taxrate = 25.06% (2.85b / 11.4b)
NOPAT = 8.75b (EBIT 11.7b * (1 - 25.06%))
Current Ratio = 1.43 (Total Current Assets 31.8b / Total Current Liabilities 22.3b)
Debt / Equity = 0.53 (Debt 16.6b / totalStockholderEquity, last quarter 31.6b)
Debt / EBITDA = 0.29 (Net Debt 3.81b / EBITDA 13.3b)
Debt / FCF = 0.33 (Net Debt 3.81b / FCF TTM 11.6b)
Total Stockholder Equity = 31.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.09% (Net Income 8.40b / Total Assets 73.6b)
RoE = 26.77% (Net Income TTM 8.40b / Total Stockholder Equity 31.4b)
RoCE = 32.06% (EBIT 11.7b / Capital Employed (Equity 31.4b + L.T.Debt 5.03b))
RoIC = 18.05% (NOPAT 8.75b / Invested Capital 48.5b)
WACC = 6.71% (E(128b)/V(144b) * Re(7.41%) + D(16.6b)/V(144b) * Rd(1.82%) * (1-Tc(0.25)))
Discount Rate = 7.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -90.75 | Cagr: -2.15%
[DCF] Terminal Value 76.30% ; FCFF base≈11.3b ; Y1≈12.0b ; Y5≈14.2b
[DCF] Fair Price = 351.0 (EV 219b - Net Debt 3.81b = Equity 215b / Shares 611.9m; r=8.35% [WACC [floored]]; 5y FCF grow 6.86% → 2.50% )
EPS Correlation: 99.04 | EPS CAGR: 7.13% | SUE: 1.32 | # QB: 4
Revenue Correlation: 98.16 | Revenue CAGR: 5.78% | SUE: 3.09 | # QB: 1
EPS current Quarter (2026-11-30): EPS=3.94 | Chg30d=-1.08% | Revisions=-25% | Analysts=19
EPS next Quarter (2027-02-28): EPS=3.15 | Chg30d=-0.12% | Revisions=-22% | Analysts=21
EPS current Year (2027-08-31): EPS=14.67 | Chg30d=+0.23% | Revisions=-17% | GrowthEPS=+5.0% | GrowthRev=+4.3%
EPS next Year (2028-08-31): EPS=15.97 | Chg30d=+1.44% | Revisions=+0% | GrowthEPS=+8.9% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -27% (up=4, down=8)